Company intelligence / Profile preview

Shijiazhuang Sagacity New Drug Development

Shijiazhuang, Hebei, Chinachictr.org.cn ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead asset SC0191 is a novel small molecule Wee1 inhibitor that has demonstrated potent anti-tumor activity in preclinical models of TP53-mutant solid cancers such as SCLC and pancreatic cancer. SC0191 showed superior efficacy to AZD1775 in xenograft models.

Therapeutic areas: ImmunologyOncologyOther
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shijiazhuang Sagacity New Drug Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shijiazhuang Sagacity New Drug Development.

Explore the full profile